Aurinia Lifts 2026 Revenue Guidance After Q3 Sales Rise 14%
AUPH sits 44% above its 52-week low of $11.96.
Summary
Aurinia raised its 2026 total revenue guidance to $325M-$330M from $315M-$325M after Q3 revenue came in at $83.7M, up 14% year over year, and narrowed its 2026 net product sales view to $310M-$315M from $305M-$315M. LUPKYNIS net product sales were $79.4M, up 12%, while nine-month net income jumped 35% to $103.5M and diluted EPS rose 38% to $0.76. Q3 EPS was 23c, and the quarter's net income was flat at $31.7M as R&D spending nearly doubled to $16.6M, reflecting the Kezar integration and pipeline work. Cash and investments stood at $486.9M, and the company bought back 5.0M shares for $74.9M in the first nine months. On the pipeline side, Aurinia started the PRESERVE Phase 4 study combining LUPKYNIS with belimumab, obinutuzumab or anifrolumab, and aritinercept is now in development across four indications. The raised top-line range is the number that matters here — it confirms LUPKYNIS growth is holding after the Teva settlement locked out generic competition until at least December 2036.
At the time of this announcement, AUPH was trading at $17.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $11.96 to $19.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.